0001213900-18-012566.txt : 20180914 0001213900-18-012566.hdr.sgml : 20180914 20180914163825 ACCESSION NUMBER: 0001213900-18-012566 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180911 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20180914 DATE AS OF CHANGE: 20180914 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rasna Therapeutics Inc. CENTRAL INDEX KEY: 0001582249 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 392080103 STATE OF INCORPORATION: NV FISCAL YEAR END: 0929 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-191083 FILM NUMBER: 181071576 BUSINESS ADDRESS: STREET 1: 420 LEXINGTON AVENUE STREET 2: SUITE 2525 CITY: NEW YORK STATE: NY ZIP: 10170 BUSINESS PHONE: 646-396-4087 MAIL ADDRESS: STREET 1: 420 LEXINGTON AVENUE STREET 2: SUITE 2525 CITY: NEW YORK STATE: NY ZIP: 10170 FORMER COMPANY: FORMER CONFORMED NAME: Active With Me Inc. DATE OF NAME CHANGE: 20130723 8-K 1 MainDocument.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


____________________________________________________________

 

FORM 8-K 

CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


____________________________________________________________

 

Date of Report (Date of earliest event reported):  September 11, 2018


RASNA THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)


Nevada

 

333- 191083

 

39-2080103

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

 

 

 

 

 

 

 

 

420 Lexington Avenue, Suite 2525, New York, NY

 

10170

(Address of principal executive offices)

 

(Zip Code)


Registrant’s telephone number, including area code: 646-396-4087

 

 

(Former name or former address, if changed since last report)

Copies to:

Jeffrey Fessler, Esq.

Sheppard, Mullin, Richter & Hampton LLP

30 Rockefeller Plaza

New York, New York 10112

Telephone: (212) 653-8700

Facsimile: (212) 653-8701


 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒


 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Compensatory Arrangements of Certain Officers.

 

           On September 11 and 12, 2018, Dr. Riccardo Dalla-Favera and James Mervis, respectively, resigned as directors of Rasna Therapeutics, Inc. (the “Company”) for personal reasons.  Each of Dr. Dalla-Favera’s and Mr. Mervis’s resignation is not a result of any disagreement with the Company, the Company’s management or the Board of Directors.

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date:  September 14, 2018

 

 

 

 

 

 

 

RASNA THERAPEUTICS, INC.

 

 

 

 

 

 

By: 

/s/  Kunwar Shailubhai

 

 

 

Name:  Kunwar Shailubhai

 

 

 

Title:    Chief Executive Officer

 

 

 

 

 
2